Jordan Feld, M.D., MPH, FAASLD

Jordan Jay Feld, MD, MPH, FAASLD is Interim Director of the Toronto Centre for Liver Disease at the Toronto General Hospital. Dr. Feld is a Professor of Medicine and holds the R. Phelan Chair in Translational Liver Research at the University of Toronto, where he also serves as Research Director for Hepatology, overseeing and coordinating all research activities for liver disease.

Dr Feld serves on a number of committees for the AASLD, including the Hepatitis B Special Interest Group and the Viral Hepatitis Elimination Task Force (US).  He also serves on the Hepatitis Steering Committee of the AIDS Clinical Trials Group Network Coordinating Center/Hepatitis Transformative Science Group.

Dr Feld is involved in clinical and laboratory-focused translational research focused on strategies to improve therapy and diagnostics for viral hepatitis, helping to develop new treatments for HBV, serving as principal investigator and co-investigator on numerous trials in both HBV and HCV.

Dr Feld has coauthored numerous journal articles, abstracts, and book chapters on the prevention of viral hepatitis transmission, long-term nucleotide analogue therapy in chronic hepatitis B, and hepatitis B vaccination.

  • Feld JJ, Wahed AS, Fried M, et al; Hepatitis B Research Network (HBRN). Withdrawal of long-term nucleotide analog therapy in chronic hepatitis B: outcomes from the withdrawal phase of the HBRN Immune Active treatment trial. Am J Gastroenterol. 2023 May 5. doi:10.14309/ajg.0000000000002176
  • Howell J, Seaman C, Wallace J, et al. Pathway to global elimination of hepatitis B: HBV cure is just the first step. Hepatology. 2023 May 1. doi:10.1097/HEP.0000000000000430
  • Feld JJ, Lok AS, Zoulim F. New perspectives on development of curative strategies for chronic hepatitis B. Clin Gastroenterol Hepatol. 2023 Apr 18:S1542-3565(23)00279-3. doi:10.1016/j.cgh.2023.02.032